InfoBionic's second-generation MoMe® Kardia device, a single 3-in-1 device which streams full disclosure cardiac arrhythmia detection and monitoring data using cellular technology, is already commercially available. Harnessing the power of the Cloud to deliver actionable, on-demand results directly to physicians, it transforms the efficiency and economics of cardiac arrhythmia detection and monitoring with an innovative Software as a Service (SaaS) model. BioTelemetry agreed that InfoBionic's second-generation MoMe® Kardia system is unaffected by the judgment.
InfoBionic is pleased to have dispensed with part of the pending litigation and will vigorously defend its transformative MoMe® Kardia platform against BioTelemetry's remaining claims. At this time, the U.S. Patent Office already has found that InfoBionic demonstrated a reasonable likelihood that it will prevail in having claims of two BioTelemetry patents declared invalid, and a motion to invalidate the remaining asserted patents is pending in court.
InfoBionic is an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. For more information please visit www.infobionic.com.
Logo - http://photos.prnewswire.com/prnh/20160315/344729LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infobionic-successfully-resolves-obsolete-patent-claims-300302045.html
SOURCE InfoBionic, Inc.